1. Among patients with severe aortic stenosis at low-risk for surgery, transcatheter aortic valve replacement (TAVR) with a self-expanding valve was noninferior to surgical aortic valve replacement (SAVR) with respect to a composite of all-cause mortality or disabling stroke at 24 months.
2. While all-cause mortality was similar between TAVR and SAVR at 24 months, the incidence of disabling stroke, atrial fibrillation, and acute kidney injury was significantly less with TAVR while rates of pacemaker implantation was less in the SAVR group.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Though transcatheter aortic valve replacement (TAVR) was originally developed as a treatment option for high-risk patients with severe aortic stenosis, its indications have expanded to intermediate-risk patients on an individualized basis; however, limited evidence exists in the low-risk patient population. The Evolut Low Risk trial was designed to assess the safety and efficacy of TAVR using a self-expandable valve in this low-risk surgical cohort. This reports the results from the prespecified interim analysis of the Evolut trial, which randomized patients with severe aortic stenosis and a three percent or less predicted 30-day surgical mortality risk to either TAVR with a self-expanding valve or surgical aortic valve replacement (SAVR). TAVR was found to be noninferior with respect to the primary endpoint – a composite of death or disabling stroke at 24 months – but did not meet the prespecified criterion for superiority. Among key secondary endpoints, TAVR was found to have a significantly lower incidence of disabling stroke at 24 months, new-onset atrial fibrillation, acute kidney injury (AKI), and severe bleeding. Higher rates of permanent pacemaker implantation and moderate to severe aortic regurgitation were found in the TAVR group. This landmark trial, published alongside results from the PARTNER 3 trial on TAVR with balloon-expandable valves versus surgery, suggests that low-risk surgical patients do as well and perhaps better with TAVR compared to SAVR over two years.
This was the preliminary analysis from a multicenter, randomized trial that used an adaptive Bayesian design. The study provides data for the largest patient cohort currently being treated with SAVR. It is further strengthened by its publication alongside similar results from the PARTNER 3 trial. The main limitation is that only a minority of patients had reached the complete 24-month follow-up. Additional long-term data is needed before making definitive conclusions.
Click to read the study in NEJM
Relevant Reading: Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients
In-Depth [randomized controlled trial]: This was a multinational, noninferiority trial that randomized patients with severe aortic-valve stenosis and 3% predicted 30-day risk of death with surgery in a 1:1 ratio to TAVR with one of three self-expanding, supraannular bioprostheses (n=725) or SAVR (n=678). The primary endpoint was noninferiority of TAVR compared to SAVR with respect to a composite of death from any cause or disabling stroke at 24 months. Secondary endpoints included a 30-day composite safety endpoint (death, disabling stroke, life-threatening bleeding, major vascular complications, and stage 2/3 kidney injury), the primary endpoint and individual components at 30 days, life-threatening bleeding at 30 days, permanent pacemaker implantation at 30 days, and new-onset atrial fibrillation at 30 days, among others. Hemodynamic assessment included mean valve gradients, effective orifice area, and aortic regurgitation at 30 days.
For this prespecified interim analysis, 12-month follow-up data was available for 432 patients in the TAVR group (n=72 for 24-month follow-up) and 352 in the SAVR group (n=65 for 24-month follow-up). The incidence of the primary endpoint was 5.3% (95% Bayesian credible interval [BCI], 3.3 to 8.0) in the TAVR group vs. 6.7% (95% BCI, 4.4 to 9.6) in the SAVR group, which met the prespecified noninferiority threshold (posterior probability of noninferiority, >0.999) but not superiority (posterior probability of superiority, >0.779). TAVR demonstrated a significantly reduced incidence of the 30-day secondary safety endpoint (5.3% vs. 10.7% with SAVR), new-onset atrial fibrillation (7.7% vs. 35.4%), life-threatening bleeding (2.4 vs. 7.5%), and AKI (0.9% vs. 2.8%). A higher incidence of permanent pacemaker implantation (17.4% vs. 6.1% at 30 days) at one year and moderate to severe aortic regurgitation was found in the TAVR group. TAVR was also reported to have a smaller mean aortic gradient (8.6 mmHg vs. 11.2 mmHg with SAVR) and greater mean effective orifice area (2.3 vs. 2.0) at one year.
Image: PD
©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc
